<DOC>
	<DOCNO>NCT00359294</DOCNO>
	<brief_summary>Phase I trial , dose escalating , prospective , open-label , non-randomized , multicenter study . The purpose determine safety , tolerability , dose limit toxicity ( DLT ) recommend dose ( RD ) PM00104 , administer intravenously 1 hour daily 5 day every 3 week ( consider 1 cycle ) subject advance malignant solid tumor lymphoma .</brief_summary>
	<brief_title>A Phase I Study Zalypsis ( PM00104 ) Subjects With Advanced Malignant Solid Tumors Lymphoma</brief_title>
	<detailed_description>Phase I trial , dose escalating , prospective , open-label , non-randomized , multicenter study . The purpose determine safety , tolerability , dose limit toxicity ( DLT ) recommend dose ( RD ) PM00104 , administer intravenously 1 hour daily 5 day every 3 week ( consider 1 cycle ) subject advance malignant solid tumor lymphoma . Secondary objective determine preliminary pharmacokinetics PM00104 , evaluate relationship pharmacokinetics/pharmacodynamics evaluate preliminary antitumor activity PM00104 . Dose-escalation guideline follow accelerated phase I design conventional cytotoxic agent order minimize number subject treat subtoxic dose level . The trial conduct compliance protocol , GCP applicable regulatory requirement .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>1 . Voluntary write informed consent subject obtain studyspecific procedure . 2 . Histologically cytologically confirm malignant solid tumor lymphoma . 3 . Subjects malignancy otherwise curable effective standard therapy exist . 4 . Age ≥ 18 year . 5 . Subject measurable nonmeasurable disease use RECIST criterion 6 . Recovery drugrelated adverse event relate previous treatment , exclude alopecia NCICTCAE grade &lt; 2 peripheral neuropathy . 7 . Laboratory value within 7 day prior first infusion : Platelet count ≥ 100 x109/L , hemoglobin ≥ 9 g/dL absolute neutrophil count ( ANC ) ≥ 1.5 x109/L . Alkaline phosphatase ≤ 2.5 x upper limit normal ( ULN ) ( ≤ 5 x ULN case extensive bone metastasis ) Aspartate aminotransferase ( AST ) : ≤ 2.5 x ULN Alanine aminotransferase ( ALT ) : ≤ 2.5 x ULN Total bilirubin : ≤ 1.5 ULN , unless due Gilbert 's syndrome . Creatinine : ≤ ULN , calculate creatinine clearance : ≥ 60 mL/min ( calculate CockcroftGault formula ; see Appendix III ) . Albumin : ≥ 2.5 g/dL . Partial tromboplastin within normal limit institution INR within normal limit institution ( unless due oral anticoagulation ) 8 . Performance status ( ECOG ) ≤ 1 9 . Life expectancy ≥ 3 month . 10 . Left ventricular ejection fraction ( LVEF ) within normal limit institution ( LVEF least 50 % ) . 11 . Women childbearing potential must negative serum pregnancy test study entry . Both men woman must agree use medically acceptable method contraception throughout treatment period 3 month discontinuation treatment . Acceptable method contraception include complete abstinence , IUD , oral contraceptive , subdermal implant double barrier ( condom contraceptive sponge contraceptive suppository ) . 1 . Prior therapy PM00104 2 . Pregnant lactating woman . 3 . Less 4 week radiation therapy ( 8 week case extensive prior radiotherapy ) last dose hormonal therapy , biological therapy chemotherapy ( 6 week case nitrosourea , mitomycin C ) . 4 . Prior high dose chemotherapy need bone marrow transplant support . 5 . Subjects untreated uncontrolled brain meningeal metastasis . 6 . Other relevant disease adverse clinical condition : Increased cardiac risk define : History presence unstable angina . History presence myocardial infarction . Congestive heart failure . Symptomatic arrhythmia arrhythmia require ongoing treatment . Abnormal ECG ( i.e. , patient follow exclude : QT prolongationQTc &gt; 480 msec , sign cardiac enlargement hypertrophy , bundle branch block , partial bundle branch block , sign ischemia necrosis , WolffParkinsonWhite pattern ) . History presence valvular heart disease . Uncontrolled arterial hypertension despite optimal medical therapy . Previous mediastinal radiotherapy . Previous treatment doxorubicin cumulative dos excess 400 mg/m2 History significant neurological psychiatric disorder . Active infection . Significant nonneoplastic liver disease ( e.g. , cirrhosis , chronic active hepatitis ) . Significant nonneoplastic renal disease . Immunocompromised subject , include subject know infected human immunodeficiency virus ( HIV ) . Uncontrolled endocrine disease ( e.g. , diabetes mellitus , hypothyroidism hyperthyroidism , adrenal disorder ) require relevant change medication within last month hospital admission within last 3 month . Any major illness , investigator 's judgment , could substantially increase risk associate subject 's participation study . 7 . Limitation subject 's ability comply treatment followup participate center . Subjects register trial must treat follow participate center . 8 . Treatment investigational product 30 day period prior first infusion . 9 . Known hypersensitivity component drug product , include sucrose potassium phosphate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Tumor</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Zalypsis</keyword>
	<keyword>PharmaMar</keyword>
	<keyword>PM00104</keyword>
</DOC>